A Comprehensive Report on the Investigational Drug Serelaxin (DB05794)

Section 1: Executive Summary

Serelaxin (DrugBank ID: DB05794) is an investigational biotech drug developed as a recombinant form of human relaxin-2, a pleiotropic peptide hormone. It was investigated by Novartis, under the codename RLX030 and the proposed brand name Reasanz, primarily for the treatment of acute heart failure (AHF).[1] The scientific rationale for its development was compelling, based on its mechanism as a relaxin receptor (RXFP1) agonist that mimics the profound cardiovascular and renal adaptations observed during pregnancy. Its proposed benefits in AHF stemmed from its multifaceted physiological effects, including systemic and renal vasodilation, anti-inflammatory actions, and anti-fibrotic properties, driven by the activation of nitric oxide and cAMP signaling pathways.[4]

The clinical development program for Serelaxin in AHF was defined by two pivotal, large-scale Phase III trials with starkly contrasting outcomes. The initial trial, RELAX-AHF, produced ambiguous results on its primary dyspnea endpoints but generated significant optimism due to a promising, albeit exploratory, 37% reduction in 180-day mortality.[7] This finding prompted the initiation of a much larger confirmatory trial, RELAX-AHF-2, which was designed to definitively establish this mortality benefit. However, RELAX-AHF-2 failed to meet either of its co-primary endpoints, showing no statistically significant effect on cardiovascular mortality at 180 days or on the incidence of worsening heart failure through day 5.[9]

This definitive clinical failure led to the termination of the drug's development for AHF. Serelaxin failed to gain marketing approval from major global regulatory bodies. The European Medicines Agency (EMA) refused authorization for Reasanz, citing insufficient evidence of efficacy based on a single trial with ambiguous endpoints and methodological concerns.[1] Similarly, despite an initial Breakthrough Therapy designation, the U.S. Food and Drug Administration (FDA) process culminated in a unanimous advisory committee vote against approval, followed by a Complete Response Letter that mandated further evidence of efficacy.[12]

The trajectory of Serelaxin, from a molecule with a strong biological rationale and positive biomarker data to a late-stage clinical and regulatory failure, serves as a significant and cautionary case study in cardiovascular drug development. It highlights the immense challenges of translating favorable pharmacodynamic effects into reproducible, clinically meaningful outcomes in the complex and heterogeneous syndrome of AHF and underscores the stringent evidentiary standards required by global regulators for new therapies in this high-unmet-need population.

Section 2: Molecular Profile and Biologic Characteristics

2.1 Identification and Physicochemical Properties

Serelaxin is a biologic drug classified as a recombinant peptide hormone.[14] As an investigational compound, it has been assigned numerous identifiers across various chemical and pharmacological databases to ensure unambiguous tracking throughout its research and development lifecycle. Its fundamental properties are summarized in Table 1.

Table 1: Key Identifiers and Physicochemical Properties of Serelaxin

Property	Value	Source(s)
International Nonproprietary Name (INN)	Serelaxin	1
DrugBank ID	DB05794	1
CAS Number	99489-94-8	1
Drug Type	Biotech, Peptide, Hormone	14
Synonyms	Recombinant human relaxin, Human relaxin-2 (relaxin h2), RLX030, Reasanz, ConXn	2
Chemical Formula	C256​H408​N74​O74​S8​	1
Average Molecular Weight	5963.00 g/mol (approx. 6 kDa)	1
Monoisotopic Mass	5958.8203405 Da	1
Formulation	Sterile concentrate for solution for intravenous infusion	1

The compound was developed by Novartis under the internal codename RLX030 and the proposed trade name Reasanz for the European market.[1] Its chemical formula and high molecular weight are characteristic of a complex polypeptide structure. It was formulated as a solution for intravenous administration, reflecting its intended use in the acute inpatient setting.[1]

2.2 Structure and Composition of a Recombinant Peptide Hormone

Serelaxin is structurally and sequentially identical to the mature, naturally occurring human relaxin-2 (H2 relaxin) peptide hormone.[20] Its architecture is that of a heterodimer, composed of two distinct polypeptide chains, an A-chain and a B-chain, which are covalently linked through disulfide bonds in a manner analogous to insulin.[1]

• A-Chain (Light Chain): The A-chain consists of 24 amino acids. Its sequence is Gln-Leu-Tyr-Ser-Ala-Leu-Ala-Asn-Lys-Cys-Cys-His-Val-Gly-Cys-Thr-Lys-Arg-Ser-Leu-Ala-Arg-Phe-Cys. A common post-translational modification occurs at the N-terminus, where the initial glutamine (Gln) residue cyclizes to form pyroglutamic acid ([Glp]).[15]
• B-Chain (Heavy Chain): The B-chain is composed of 29 amino acids with the sequence Asp-Ser-Trp-Met-Glu-Glu-Val-Ile-Lys-Leu-Cys-Gly-Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Cys-Gly-Met-Ser-Thr-Trp-Ser.[1]

The tertiary structure and biological stability of Serelaxin are critically dependent on three specific disulfide bonds that cross-link these chains.[15] Two of these are inter-chain linkages, connecting cysteine residues at position 11 of the A-chain to position 11 of the B-chain (

A11​−B11​) and position 24 of the A-chain to position 23 of the B-chain (A24​−B23​). The third is an intra-chain bond within the A-chain, linking the cysteine residues at positions 10 and 15 (A10​−A15​).[15] This complex arrangement of disulfide bridges is essential for maintaining the correct three-dimensional conformation required for high-affinity binding to its cognate receptor. The significant size and conformational flexibility of this 53-amino acid peptide make its three-dimensional structure difficult to model computationally, as noted by the disallowance of conformer generation in the PubChem database.[1]

2.3 Biotechnological Production and Formulation

Serelaxin is a product of modern biotechnology, manufactured using recombinant DNA technology rather than being extracted from natural sources.[20] The chosen production host is the bacterium

Escherichia coli (E. coli), a common and well-characterized system for producing non-glycosylated recombinant proteins.[20]

The natural biosynthesis of relaxin involves a single-chain precursor, preprorelaxin, which follows a structural organization of Signal peptide—B-chain—Connecting (C)-peptide—A-chain.[24] In human cells, this precursor is processed proteolytically to remove the signal and C-peptides after the correct disulfide bonds have formed, yielding the mature, active two-chain hormone.[24]

Replicating this complex process in a prokaryotic host like E. coli presents significant manufacturing challenges. E. coli lacks the sophisticated cellular machinery for efficiently folding complex eukaryotic proteins and forming multiple disulfide bonds. Consequently, high-level expression often results in the misfolded protein aggregating into dense, insoluble, and biologically inactive particles known as inclusion bodies.[24] This necessitates a multi-step, often inefficient, downstream process to recover the active drug. This process typically involves harvesting the inclusion bodies, solubilizing the denatured protein, and then carefully refolding it under specific chemical conditions to facilitate the correct formation of the three critical disulfide bonds.[27]

Early production strategies were particularly cumbersome, requiring separate E. coli fermentations to produce the A-chain and B-chain individually. The two purified chains were then combined in a subsequent chemical reaction to induce oxidative folding and combination.[24] This dual-fermentation approach was complex and likely limited overall yield. A significant advancement in the manufacturing process, detailed in patent filings, involved the design of a non-naturally occurring single-chain prorelaxin precursor. This engineered molecule, comprising the B-chain, a novel linker peptide (a non-natural C-chain), and the A-chain, was specifically designed to be expressed in a single

E. coli fermentation and to fold more efficiently into a stable intermediate. This prohormone could then be purified and enzymatically cleaved to remove the linker, yielding the final, biologically active two-chain Serelaxin in greater yields and with higher purity.[24] This evolution in bioprocess engineering demonstrates how the inherent molecular complexity of a biologic drug directly drives innovation in its manufacturing strategy to make large-scale, commercially viable production feasible.

The final purified product is a non-glycosylated, disulfide-linked heterodimer.[19] It is formulated as a lyophilized powder that is reconstituted into a sterile solution for continuous intravenous infusion.[20] Quality control specifications ensure high purity (>97%) and low levels of endotoxin contamination, consistent with standards for parenteral biologic drugs.[25]

Section 3: Preclinical and Clinical Pharmacology

3.1 Mechanism of Action: A Pleiotropic Vasoactive Peptide

Serelaxin exerts its biological effects as a potent and specific agonist of the Relaxin/Insulin-Like Family Peptide Receptor 1 (RXFP1), formerly known as LGR7.[5] RXFP1 is a Class I leucine-rich repeat-containing G protein-coupled receptor (GPCR) that is widely distributed in tissues relevant to cardiovascular homeostasis, including the heart, kidneys, and the endothelial lining of blood vessels.[4] The binding of Serelaxin to RXFP1 initiates a cascade of intracellular signaling events that collectively mediate its diverse and pleiotropic pharmacological actions.

The primary signaling pathways activated by Serelaxin include:

1. Nitric Oxide (NO) Signaling: A cornerstone of Serelaxin's vasodilatory effect is its ability to increase the production of nitric oxide, a powerful endogenous vasodilator. Receptor activation leads to the upregulation and phosphorylation of endothelial nitric oxide synthase (eNOS), the enzyme responsible for synthesizing NO from L-arginine. The resulting increase in local NO concentration causes relaxation of vascular smooth muscle, leading to vasodilation.[4]
2. Cyclic Adenosine Monophosphate (cAMP) Pathway: Like many GPCRs, RXFP1 activation is coupled to the stimulation of adenylate cyclase, which catalyzes the conversion of ATP to the second messenger cAMP. Elevated intracellular cAMP levels activate Protein Kinase A (PKA), which in turn phosphorylates downstream targets that contribute to vasodilation and may enhance cardiac contractility and output.[6]
3. Modulation of Vasoactive Peptide Systems: Serelaxin actively shifts the balance of local vascular control toward vasodilation by counteracting potent vasoconstrictor systems. It has been shown to inhibit the signaling of angiotensin II and endothelin-1 (ET-1), two key mediators of vasoconstriction in heart failure. This is achieved in part by upregulating the endothelin B receptor, which mediates vasodilation.[4]
4. Vascular Endothelial Growth Factor (VEGF) Production: Serelaxin stimulates the production of VEGF, a critical signaling protein that promotes angiogenesis (the formation of new blood vessels) and maintains the health and integrity of the vascular endothelium.[28]

Beyond its direct hemodynamic effects, Serelaxin also exhibits significant anti-fibrotic and anti-inflammatory properties. It directly interferes with tissue fibrosis by inhibiting the synthesis of collagen and other extracellular matrix components while simultaneously upregulating matrix metalloproteinases (MMPs), enzymes that degrade excess matrix proteins.[1] This action is critical for preventing or reversing the pathological stiffening of cardiac and vascular tissues that contributes to heart failure progression. Furthermore, Serelaxin modulates the activity of various inflammatory cytokines and chemokines, thereby reducing the chronic inflammation and oxidative stress that drive end-organ damage in the setting of AHF.[5]

3.2 Pharmacodynamic Profile

The multifaceted mechanism of action of Serelaxin translates into a distinct pharmacodynamic profile characterized by favorable hemodynamic changes, renal enhancement, and evidence of end-organ protection. These effects provided the strong clinical rationale for its investigation as a therapy for AHF.

• Hemodynamic Effects: The primary pharmacodynamic effect of Serelaxin is systemic vasodilation, which is more pronounced in the arterial circulation than the venous system.[5] This leads to a clinically significant decrease in systemic vascular resistance (SVR) and an increase in systemic arterial compliance, effectively reducing the afterload against which the failing heart must pump.[5] In clinical trials involving AHF patients, these systemic effects resulted in marked improvements in intracardiac pressures. Invasive hemodynamic monitoring demonstrated that Serelaxin infusion led to a rapid and significant reduction in pulmonary capillary wedge pressure (PCWP), mean pulmonary artery pressure (PAP), and right atrial pressure (RAP).[7] This reduction in cardiac filling pressures is a direct indicator of relief from pulmonary and systemic congestion. A predictable and consistent consequence of this vasodilation is a modest reduction in both systolic and diastolic blood pressure.[4]
• Renal Effects: Serelaxin has pronounced beneficial effects on the kidneys, a vital consideration in AHF where cardiorenal syndrome is common and portends a poor prognosis. The drug increases renal blood flow, which can improve renal perfusion and oxygenation.[4] This is accompanied by an increase in the glomerular filtration rate (GFR) and enhanced natriuresis (urinary sodium excretion), which aids in fluid removal and decongestion without compromising renal function.[6]
• End-Organ Protection: A key differentiating feature of Serelaxin's proposed therapeutic benefit was its potential to protect vital organs from injury during the acute stress of an AHF episode. This hypothesis was strongly supported by consistent and statistically significant changes in a panel of organ-specific biomarkers observed across its clinical development program:
• Cardioprotection: Serelaxin treatment was associated with a reduction in plasma levels of high-sensitivity cardiac troponin T (hs-cTnT), a marker of myocyte injury, and N-terminal pro-B-type natriuretic peptide (NT-proBNP), a marker of myocardial wall stress and congestion.[7]
• Renoprotection: Treatment led to lower levels of serum creatinine and cystatin C, both established markers of renal dysfunction.[8]
• Hepatoprotection: Serelaxin was also associated with reductions in the liver enzymes aspartate transaminase (AST) and alanine transaminase (ALT), suggesting mitigation of hepatic congestion and injury.[7]

3.3 Pharmacokinetic Profile

The pharmacokinetic profile of Serelaxin has been characterized in healthy volunteers and in patient populations with heart failure, renal impairment, and hepatic impairment. As a peptide administered intravenously, its disposition in the body follows a predictable pattern for large-molecule drugs.

Table 2: Summary of Pharmacokinetic Parameters for Serelaxin

Parameter	Value / Description	Notes / Patient Population	Source(s)
Administration Route	Continuous Intravenous (IV) Infusion	Bypasses absorption phase	1
Kinetic Model	Three-compartment disposition model with central elimination	Describes multi-phasic decline in serum concentration	39
Terminal Half-Life (t½)	7–8 hours	Consistent across healthy subjects and patients with hepatic or renal impairment	29
Systemic Clearance (CL)	Median: 83.34 ml⋅h−1⋅kg−1	In pooled analysis of 1015 subjects	39
Volume of Distribution (Vss)	~347 ml/kg	Healthy Subjects	40
	~434-544 ml/kg	Chronic and Acute Heart Failure Patients	40
Effect of Renal Impairment	Moderate decrease in CL (37-52%); moderate increase in exposure (30-115%)	In patients with severe renal impairment or ESRD. No dose adjustment deemed necessary.	38
Effect of Hepatic Impairment	No effect on PK profile	In patients with mild, moderate, or severe (Child-Pugh A-C) hepatic impairment. No dose adjustment needed.	39
Metabolism	Expected to be via proteolytic degradation	Avoids cytochrome P450 (CYP) enzyme pathways, suggesting low potential for drug-drug interactions.	20

Serelaxin exhibits linear pharmacokinetics following IV administration, with serum concentrations reaching a steady state within approximately 4 to 12 hours of initiating a continuous infusion.[29] Its disposition is best described by a three-compartment model, which accounts for its distribution from the central circulation into peripheral tissues and its subsequent elimination.[39] The volume of distribution is sensitive to the patient's fluid status; consistent with its hydrophilic nature, the volume is significantly larger in patients with AHF, who are typically fluid-overloaded, compared to healthy subjects.[40]

As a peptide, Serelaxin is presumed to be cleared primarily through metabolic degradation by proteases and peptidases throughout the body into constituent amino acids, which are then re-utilized or eliminated. This metabolic pathway avoids the hepatic cytochrome P450 enzyme system, minimizing the risk of pharmacokinetic drug-drug interactions with small-molecule drugs commonly used in AHF patients.[20]

Systematic covariate analysis identified that renal function, as measured by estimated glomerular filtration rate (eGFR), has a moderate impact on Serelaxin clearance, indicating that renal elimination plays a partial role in its disposition.[39] Studies in patients with severe renal impairment and end-stage renal disease (ESRD) confirmed a moderate decrease in clearance and a corresponding increase in drug exposure.[38] However, given the drug's wide therapeutic window and shallow dose-response relationship, these changes were not considered clinically significant enough to warrant a priori dose adjustments in this population.[38] In contrast, studies in patients with varying degrees of hepatic impairment found no effect on the pharmacokinetic profile, indicating that no dose adjustments are necessary for patients with liver disease.[41]

The disconnect between Serelaxin's pharmacodynamic and clinical results is a central theme of its development story. The data clearly show that the drug was biologically active in the target AHF population. It engaged its receptor, activated downstream signaling, and produced the intended physiological responses: it lowered cardiac filling pressures, improved renal function markers, and reduced biomarkers of multi-organ injury.[8] This confirmation of target engagement and pharmacodynamic effect is a critical milestone in drug development. Yet, as detailed in the subsequent section, these positive biological and surrogate endpoint changes failed to translate into a reproducible benefit on hard clinical outcomes like mortality and rehospitalization. This divergence suggests a complex reality in AHF pathophysiology: modulating these specific hemodynamic and biomarker pathways, while seemingly beneficial, may be insufficient to alter the overall disease trajectory. The pathways targeted by Serelaxin may not be on the primary causal chain leading to long-term mortality, or the magnitude and duration of the drug's effect (a 48-hour infusion) may be inadequate to overcome the multitude of other pathological processes that drive poor outcomes in this complex, chronic disease.

Section 4: The Clinical Development Program in Acute Heart Failure

The clinical evaluation of Serelaxin for acute heart failure (AHF) was anchored by a large-scale development program, culminating in two pivotal Phase III trials: RELAX-AHF and RELAX-AHF-2. The divergent results of these two studies form the core of the drug's clinical narrative, tracing a path from initial promise to definitive failure.

4.1 The RELAX-AHF Trial: A Signal of Promise and Ambiguity

The RELAX-AHF trial (NCT00520806) was the first large-scale, Phase III study designed to evaluate the efficacy and safety of Serelaxin in patients hospitalized for AHF.[43] It was an international, randomized, double-blind, placebo-controlled trial that enrolled 1,161 patients across 96 sites.[44] Patients were randomized in a 1:1 ratio to receive a continuous 48-hour intravenous infusion of either Serelaxin at a dose of 30 µg/kg/day or a matching placebo, in addition to standard of care. A key design feature was the emphasis on early intervention, with the study drug initiated within 16 hours of the patient's presentation to the hospital.[44]

The trial targeted a specific, well-defined AHF phenotype: patients presenting with dyspnea, evidence of pulmonary congestion on chest radiograph, elevated natriuretic peptide levels (BNP or NT-proBNP), a systolic blood pressure greater than 125 mmHg, and mild-to-moderate renal dysfunction (defined as an eGFR between 30 and 75 mL/min/1.73 m2).[43] This population represents a substantial subset of AHF patients, often characterized as having hypertensive AHF with cardiorenal involvement.

The trial's primary efficacy endpoints focused on the relief of dyspnea, a primary goal of AHF treatment. The results on these endpoints were mixed, creating a degree of ambiguity in the interpretation of the drug's primary benefit:

• Endpoint Met: Serelaxin demonstrated a statistically significant improvement in dyspnea as measured by the area under the curve (AUC) of a visual analogue scale (VAS) from baseline through day 5 (19.4% improvement vs. placebo; p=0.007).[8]
• Endpoint Not Met: Serelaxin failed to show a significant benefit on the other co-primary endpoint, which was the proportion of patients reporting moderate or marked dyspnea improvement on a 7-point Likert scale at 6, 12, and 24 hours (27% vs. 26% for placebo; p=0.70).[8]

While the primary results were equivocal, the most compelling finding from RELAX-AHF emerged from the analysis of secondary and safety endpoints. The trial showed no benefit on the composite secondary endpoint of cardiovascular death or rehospitalization for heart or renal failure through day 60.[5] However, a pre-specified analysis of mortality at 180 days revealed a striking and statistically significant 37% reduction in both all-cause mortality and cardiovascular mortality in the Serelaxin group compared to placebo (Hazard Ratio 0.63; p=0.019 for all-cause death).[7] This mortality signal, though derived from a secondary/safety analysis and thus considered hypothesis-generating, was the most influential outcome of the trial. It provided a powerful rationale for further investigation and became the central hypothesis to be tested in a subsequent, larger confirmatory study. The mortality benefit was supported by data showing that Serelaxin reduced the incidence of in-hospital worsening heart failure and led to favorable changes in biomarkers of cardiac, renal, and hepatic damage.[7]

4.2 The RELAX-AHF-2 Trial: The Confirmatory Failure

To confirm the promising mortality benefit observed in RELAX-AHF, Novartis initiated the RELAX-AHF-2 trial (NCT01870778). This was a substantially larger, event-driven, multicenter, randomized, double-blind, placebo-controlled Phase IIIb study designed with statistical power to definitively assess the effect of Serelaxin on hard clinical outcomes.[2] The trial enrolled 6,545 patients hospitalized for AHF, adhering to inclusion criteria very similar to the original RELAX-AHF study. Patients were again randomized to a 48-hour infusion of Serelaxin (30 µg/kg/day) or placebo, added to standard therapy.[10]

The trial was designed with two co-primary endpoints, directly testing the key positive signals from the first study. The results were unequivocally negative, as the trial failed to meet either endpoint [9]:

1. Cardiovascular Death at 180 Days: There was no difference between the groups. Death from cardiovascular causes occurred in 8.7% of patients in the Serelaxin group and 8.9% of patients in the placebo group (HR 0.98; 95% CI 0.83–1.15; p=0.77). This result definitively refuted the hypothesis that Serelaxin provides a mortality benefit.[49]
2. Worsening Heart Failure Through Day 5: There was no statistically significant reduction in this endpoint. Worsening heart failure occurred in 6.9% of Serelaxin-treated patients versus 7.7% of placebo-treated patients (HR 0.89; 95% CI 0.75–1.07; p=0.19).[49]

Furthermore, no significant benefits were observed for any of the key secondary endpoints, including all-cause mortality at 180 days, the composite of cardiovascular death or rehospitalization for heart or renal failure, or the length of the index hospital stay.[49]

Despite the neutral clinical outcomes, a pre-specified biomarker substudy involving 1,020 patients from RELAX-AHF-2 provided clear evidence that the drug was biologically active and engaging its targets as expected.[14] In this substudy, Serelaxin treatment led to statistically significant reductions in markers of cardiac injury (troponin T), wall stress (NT-proBNP), and renal dysfunction (creatinine, cystatin C) compared to placebo. This created a critical paradox: the drug produced favorable changes in surrogate markers of organ protection but failed to alter the clinical course of the disease.

4.3 A Tale of Two Trials: Dissecting the Discrepant Outcomes

The starkly different mortality findings between RELAX-AHF and RELAX-AHF-2 demand a critical analysis to understand the discrepancy. Several factors likely contributed to the failure to replicate the initial positive signal.

The most probable explanation is that the 37% mortality reduction observed in the relatively small RELAX-AHF trial was a result of the "play of chance"—a statistically significant but spurious finding (a Type I error) that can occur in clinical research, particularly when multiple endpoints are examined.[51] The much larger and more robustly powered RELAX-AHF-2 trial, designed specifically to test this hypothesis, provided a more accurate estimate of the true effect size, which was neutral.

While the inclusion and exclusion criteria for the two trials were nearly identical, subtle but potentially meaningful differences may have existed in the baseline characteristics and risk profiles of the enrolled patient populations. A post-hoc analysis suggested that the mortality rate in the placebo arm of RELAX-AHF was unexpectedly high compared to similar populations in other AHF trials, potentially exaggerating the apparent treatment benefit. Furthermore, analyses of the causes of death revealed that the rate of non-cardiovascular mortality was higher in RELAX-AHF-2 than in RELAX-AHF, which could have diluted a potential treatment effect on cardiovascular death.[51]

The comparison of the primary and key secondary outcomes from both trials, as shown in Table 3, starkly illustrates this discrepancy.

Table 3: Head-to-Head Comparison of Primary and Key Secondary Efficacy Outcomes from the RELAX-AHF and RELAX-AHF-2 Trials

Endpoint	RELAX-AHF (N=1,161)	RELAX-AHF-2 (N=6,545)
Dyspnea Improvement (VAS AUC to Day 5)	Met (p=0.007)	Not a primary endpoint
Dyspnea Improvement (Likert Scale)	Not Met (p=0.70)	Not a primary endpoint
Worsening Heart Failure to Day 5	Reduced (Secondary finding)	Not Met (p=0.19)
CV Death or HF/RF Rehospitalization to Day 60	No significant effect	No significant effect
Cardiovascular Death to Day 180	Reduced by 37% (HR 0.63; p=0.028)	Not Met (p=0.77)
All-Cause Death to Day 180	Reduced by 37% (HR 0.63; p=0.019)	No significant effect (p=0.39)
CV=Cardiovascular; HF=Heart Failure; RF=Renal Failure; HR=Hazard Ratio; VAS=Visual Analogue Scale. Primary endpoints for each trial are in bold.
Sources: 7

Across this extensive clinical program, Serelaxin consistently demonstrated a favorable safety and tolerability profile. The adverse events observed were generally mild and consistent with the drug's known vasodilatory mechanism.

Table 4: Summary of Adverse Events and Tolerability Profile of Serelaxin

Adverse Event (AE) Category	Serelaxin Group	Placebo Group	Notes	Source(s)
Overall AEs	Similar incidence across groups	Similar incidence across groups	Generally well-tolerated in multiple trials.	9
Serious AEs	Similar incidence across groups	Similar incidence across groups	No major safety signals identified.	9
Hypotension	~2.4% (in RELAX-AHF-2)	~2.0% (in RELAX-AHF-2)	Most frequent AE related to mechanism of action; low overall incidence and not statistically different from placebo in the large trial.	20
Hypokalemia	~8.1% (in RELAX-AHF-2)	~7.5% (in RELAX-AHF-2)	Not statistically significant. Link to mechanism of action is not known.	20
Hemodilution	Higher proportion with >20% decrease in hemoglobin/hematocrit	Lower proportion	Attributed to fluid shifts from vasodilation.	20
Immunogenicity	Very low incidence (e.g., 1 patient in RELAX-REPEAT)	N/A	Anti-serelaxin antibodies were rare and non-neutralizing.	38

The safety data are crucial because they confirm that the failure of Serelaxin was not due to unacceptable toxicity or risk. Rather, it was a pure failure to demonstrate clinical efficacy, a conclusion that was reached independently by regulatory authorities on both sides of the Atlantic.

Section 5: Regulatory Trajectory and Market Access Failure

The clinical development journey of Serelaxin culminated in submissions for marketing authorization to the world's two leading regulatory bodies: the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Despite a promising scientific rationale and an initial "Breakthrough Therapy" designation from the FDA, the drug failed to secure approval in either jurisdiction due to a consensus that its clinical efficacy was not sufficiently proven.

5.1 European Medicines Agency (EMA) Review

Novartis Europharm Ltd. submitted a Marketing Authorisation Application to the EMA for Serelaxin, under the proposed trade name Reasanz, for the treatment of AHF.[1] The application was reviewed by the Committee for Medicinal Products for Human Use (CHMP). In January 2014, the CHMP adopted a negative opinion, recommending that marketing authorization be refused. Novartis requested a re-examination of this opinion, but after review, the CHMP confirmed its initial decision in May 2014, finalizing the refusal.[11]

The CHMP's decision was based on several fundamental concerns regarding the evidence of efficacy presented in the application, which relied heavily on the single RELAX-AHF trial [11]:

1. Insufficient Evidence from a Single Trial: The committee concluded that data from a single pivotal study were insufficient to robustly establish the drug's effectiveness, a standard concern for new molecular entities seeking approval based on a limited data package.[11]
2. Ambiguous Clinical Benefit on Primary Endpoints: The CHMP noted the split result on the co-primary dyspnea endpoints. While a benefit was shown over 5 days using the VAS scale, no benefit was seen in the short term (up to 24 hours) using the Likert scale. The committee was not convinced of the clinical relevance of the 5-day finding and concluded that a clear, consistent benefit on symptoms had not been demonstrated.[1]
3. Methodological and Statistical Concerns: The committee raised significant questions about the statistical analysis used in the RELAX-AHF trial. Specifically, they were concerned about the method of imputing data for patients who died or experienced worsening heart failure. This approach, where assigned values are used in place of actual data, was viewed as a potential source of bias that could have influenced the results.[11]
4. Potential Confounding from Background Therapy: The CHMP questioned whether potential imbalances in the standard-of-care treatments received by patients in the Serelaxin and placebo arms could have confounded the study's results.[11]

Ultimately, the EMA's position was clear: while the safety profile of Serelaxin appeared acceptable, the benefits had not been sufficiently demonstrated to outweigh the risks and uncertainties. The evidence provided was not considered strong enough to support marketing authorization.[11]

5.2 U.S. Food and Drug Administration (FDA) Review

The regulatory journey of Serelaxin in the United States began with considerable optimism. In June 2013, based on the promising 180-day mortality data from the RELAX-AHF trial, the FDA granted Serelaxin its prestigious Breakthrough Therapy designation.[54] This designation is intended to expedite the development and review of drugs for serious conditions where preliminary clinical evidence indicates a substantial improvement over available therapies.

However, this initial optimism dissipated as the Biologics License Application (BLA) underwent rigorous review. In March 2014, the FDA's Cardiovascular and Renal Drugs Advisory Committee (CRDAC) convened to review the application. Briefing documents prepared by FDA staff and released prior to the meeting recommended against approval, echoing many of the same concerns raised by their European counterparts.[12] The FDA reviewers highlighted the insufficiency of evidence from a single trial, the failure to meet one of the two co-primary endpoints, and the "vague" and subjective nature of the "worsening heart failure" endpoint that had shown a positive signal.[54]

Following the presentation of data and public discussion, the advisory committee voted unanimously, 11-0, against recommending approval for Serelaxin.[12] The panelists acknowledged that the drug appeared to have a biological effect and that the data were "promising" and "intriguing," but they concluded that the evidence from the single RELAX-AHF trial was hypothesis-generating at best and did not meet the substantial evidence standard required for approval.[54]

Following the decisive negative recommendation from its advisory committee, the FDA issued a Complete Response Letter (CRL) to Novartis in May 2014.[13] A CRL is an official communication from the agency indicating that the application cannot be approved in its present form. The letter formally stated that further evidence on the efficacy of Serelaxin was required before a U.S. license could be granted.[13] This decision effectively placed the drug's approval on hold pending the results of the ongoing, larger RELAX-AHF-2 trial. When that trial subsequently failed to meet its endpoints, the development program for Serelaxin in AHF was terminated.

5.3 Synthesis of Regulatory Failure

The rejection of Serelaxin by both the EMA and the FDA was not due to disparate interpretations of the data but rather a remarkable transatlantic consensus on fundamental evidentiary standards. Both agencies independently identified the same core deficiencies in the regulatory submission. The primary flaw was the over-reliance on a single pivotal trial (RELAX-AHF) that yielded ambiguous results on its primary endpoints and a mortality signal that, while intriguing, was considered exploratory and required confirmation. Neither agency was willing to grant approval based on this foundation. This demonstrates a harmonized and high regulatory bar for new therapies in AHF, where robust, reproducible evidence of clinically meaningful benefit from at least one, and typically two, adequate and well-controlled trials is the expectation.

Furthermore, the Serelaxin case serves as a powerful illustration of the nature of the FDA's Breakthrough Therapy designation. While the designation provides enhanced communication with the agency and a commitment to a more efficient review, it does not lower the statutory requirements for demonstrating safety and efficacy. A drug with this designation must still stand on the merits of its data, and the Serelaxin BLA was ultimately judged to be insufficient. The journey from a "breakthrough" candidate to a rejected application highlights that promising early signals must be unequivocally confirmed by subsequent robust evidence to achieve market access.

Section 6: Synthesis and Future Perspectives

6.1 Serelaxin in Context: A Cautionary Tale in Drug Development

The story of Serelaxin is a quintessential narrative of promise and disappointment in modern pharmaceutical research. It began with an elegant and compelling biological rationale: harnessing the power of a natural hormone, relaxin-2, to mimic the beneficial cardiorenal adaptations of pregnancy to treat the pathological state of acute heart failure.[4] This rationale was supported by strong pharmacodynamic data showing that the recombinant drug, Serelaxin, was biologically active and produced the desired physiological effects, including vasodilation, improved renal function, and a reduction in biomarkers of end-organ damage.[8]

The trajectory of the development program was irrevocably shaped by the results of the first Phase III trial, RELAX-AHF. While its primary symptomatic endpoints were ambiguous, the trial generated a powerful, albeit exploratory, signal of a 37% reduction in 180-day mortality.[8] This finding fueled immense optimism and led to the investment in a massive, 6,500-patient confirmatory trial, RELAX-AHF-2. The definitive failure of this second trial to replicate the mortality benefit or show a significant effect on other hard clinical outcomes marked the end of the program.[9]

The legacy of Serelaxin is therefore that of a profound cautionary tale. It underscores the peril of building a late-stage development strategy around an exploratory finding from a single study, especially in a complex disease like AHF where outcomes are driven by myriad factors. It vividly illustrates the "valley of death" in drug development, where a compound with a strong mechanism of action and positive surrogate endpoint data can fail to deliver a meaningful clinical benefit. The Serelaxin program represents a significant investment of resources that ultimately did not yield a new therapy for patients, serving as a stark reminder of the high attrition rates in late-stage clinical research.

6.2 Implications for Future Acute Heart Failure Research

The lessons learned from the Serelaxin clinical development program have important implications for the future design of AHF clinical trials and the development of novel therapies for this condition.

• Rethinking Clinical Trial Endpoints: The Serelaxin experience highlights the critical need for robust, clinically meaningful, and reproducible endpoints in AHF research. The ambiguity of the dyspnea endpoints in RELAX-AHF weakened the overall evidence package.[11] More importantly, the stark disconnect between the positive biomarker results in the RELAX-AHF-2 substudy and the neutral clinical outcomes calls into question the utility of these markers as surrogate endpoints for long-term benefit.[14] While biomarkers like NT-proBNP and troponin are valuable for diagnosis and prognosis, improving them does not automatically translate to improved patient survival. Future programs must focus on demonstrating an impact on hard clinical outcomes, primarily all-cause mortality and heart failure hospitalizations.
• The Importance of Patient Phenotyping: Acute heart failure is not a single disease but a heterogeneous clinical syndrome with multiple underlying pathophysiologies. The RELAX-AHF trials focused on a specific phenotype of normotensive or hypertensive AHF with renal dysfunction.[45] While this was a rational approach, the neutral results suggest that even within this subgroup, the response to therapy is not uniform. Future research will likely require more sophisticated patient stratification, potentially using advanced imaging or multi-biomarker panels, to identify patient subsets who are most likely to benefit from a specific therapeutic mechanism.
• The Challenge of Short-Term Intervention for a Chronic Disease: A fundamental question raised by the Serelaxin program is whether a short, 48-hour infusion of a vasoactive agent during an acute hospitalization can realistically be expected to fundamentally alter the long-term (180-day) trajectory of what is ultimately a chronic, progressive disease.[53] While acute decongestion and organ protection are vital goals, they may be insufficient to overcome the underlying drivers of long-term morbidity and mortality. This suggests that future therapeutic strategies may need to bridge the gap between inpatient and outpatient care, perhaps by initiating therapies in the hospital that can be continued long-term. The subsequent investigation of long-acting relaxin analogs, such as AZD3427 for subcutaneous administration, represents a direct evolution of this concept, aiming to provide a more sustained biological effect to potentially influence the chronic course of heart failure.[62]

Works cited

1. Serelaxin | C256H408N74O74S8 | CID 71300755 - PubChem, accessed September 22, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Serelaxin
2. Study Details | NCT01870778 | Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF | ClinicalTrials.gov, accessed September 22, 2025, https://clinicaltrials.gov/study/NCT01870778
3. Union Register of medicinal products - Public health - European Commission, accessed September 22, 2025, https://ec.europa.eu/health/documents/community-register/html/ho25130.htm
4. Serelaxin - Wikipedia, accessed September 22, 2025, https://en.wikipedia.org/wiki/Serelaxin
5. Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection - PMC, accessed September 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4853824/
6. What is the mechanism of Serelaxin? - Patsnap Synapse, accessed September 22, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-serelaxin
7. Serelaxin: insights into its haemodynamic, biochemical, and clinical effects in acute heart failure - Oxford Academic, accessed September 22, 2025, https://academic.oup.com/eurheartj/article/35/7/410/442774
8. Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program: Correlation With Outcomes - JACC Journals, accessed September 22, 2025, https://www.jacc.org/doi/10.1016/j.jacc.2012.11.005
9. The RELAX-AHF-2 trial: serelaxin provides no mortality benefit in acute heart failure patients, accessed September 22, 2025, https://www.2minutemedicine.com/the-relax-ahf-2-trial-serelaxin-provides-no-mortality-benefit-in-acute-heart-failure-patients/
10. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study - PubMed, accessed September 22, 2025, https://pubmed.ncbi.nlm.nih.gov/28452195/
11. Reasanz | European Medicines Agency (EMA), accessed September 22, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/reasanz
12. FDA advisory panel rejects Novartis' heart failure drug serelaxin - FirstWord Pharma, accessed September 22, 2025, https://firstwordpharma.com/story/1125595
13. FDA rejects Novartis heart failure drug serelaxin - PharmaTimes, accessed September 22, 2025, https://pharmatimes.com/news/fda_rejects_novartis_heart_failure_drug_serelaxin_1001949/
14. Serelaxin - Drug Targets, Indications, Patents - Patsnap Synapse, accessed September 22, 2025, https://synapse.patsnap.com/drug/a26f18c5a2ea482a860fc02989ba071a
15. KEGG DRUG: Serelaxin, accessed September 22, 2025, https://www.genome.jp/dbget-bin/www_bget?dr:D10488
16. SID 347910234 - PubChem, accessed September 22, 2025, https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=347910234
17. Carbosynth LLC. Relaxin-2 (Human) (50µg vial), CAS# 99489-94-8, MF= C256H408N74O74S8, | Fisher Scientific, accessed September 22, 2025, https://www.fishersci.com/shop/products/relaxin-2-human-50-g-vial/501952420
18. Serelaxin (RLX030) | CAS 99489-94-8 | AbMole BioScience, accessed September 22, 2025, https://www.abmole.com/products/serelaxin.html
19. Human Relaxin-2 Recombinant Protein (130-15-25UG) - Thermo Fisher Scientific, accessed September 22, 2025, https://www.thermofisher.com/proteins/product/Human-Relaxin-2-Recombinant-Protein/130-15-25UG
20. Reasanz, INN serelaxin, accessed September 22, 2025, https://ec.europa.eu/health/documents/community-register/2014/20140805129042/anx_129042_en.pdf
21. REASANZ™ (serelaxin) Injection 1 mg/mL Solution for I.V. Infusion Novartis Pharmaceuticals Corporation The brand name of the n - CMS, accessed September 22, 2025, https://www.cms.gov/files/document/fy-15-new-tech-tracking-formspdf
22. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study - PMC - PubMed Central, accessed September 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5488179/
23. The Minimal Active Structure of Human Relaxin-2 - PMC, accessed September 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3199501/
24. EP0707650B1 - Process for producing human relaxin - Google ..., accessed September 22, 2025, https://patents.google.com/patent/EP0707650B1/en
25. Recombinant Human Relaxin-2 (B-29/A-24) Protein - R&D Systems, accessed September 22, 2025, https://www.rndsystems.com/products/recombinant-human-relaxin-2-b-29-a-24-protein_6586-rn
26. Recombinant Human Relaxin-2 - Leinco Technologies, accessed September 22, 2025, https://www.leinco.com/p/recombinant-human-relaxin-2/
27. Production of human pro-relaxin H2 in the yeast Pichia pastoris - PMC, accessed September 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5237503/
28. Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial | Cardiovascular Research | Oxford Academic, accessed September 22, 2025, https://academic.oup.com/cardiovascres/article/117/1/320/5739335
29. Serelaxin in clinical development: past, present and future - PMC, accessed September 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5406292/
30. pmc.ncbi.nlm.nih.gov, accessed September 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3875246/#:~:text=It%20exerts%20its%20effects%20by,endothelial%20cells%20of%20the%20vasculature.&text=Receptor%20binding%20activates%20and%20upregulates,)%2C%20and%20nitric%20oxide%20production.%252C%2520and%2520nitric%2520oxide%2520production.&sa=D&source=editors&ust=1758543501072605&usg=AOvVaw20mJ8_uikkbw6aqJi1SkeY)
31. Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence - PubMed, accessed September 22, 2025, https://pubmed.ncbi.nlm.nih.gov/27727514/
32. Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection - Oxford Academic, accessed September 22, 2025, https://academic.oup.com/ehjcvp/article/2/2/119/2397880
33. Figure 1 from Therapeutic effects of serelaxin in acute heart failure. | Semantic Scholar, accessed September 22, 2025, https://www.semanticscholar.org/paper/Therapeutic-effects-of-serelaxin-in-acute-heart-Du-Hewitson/2ad37eb3b1a03b583de09e9f9abe867614654eb0/figure/0
34. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure - Oxford Academic, accessed September 22, 2025, https://academic.oup.com/eurheartj/article/35/7/431/442146
35. Renal Hemodynamic Effects of Serelaxin in Patients With Chronic Heart Failure | Circulation, accessed September 22, 2025, https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.114.001536
36. Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF, accessed September 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4988995/
37. End-organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure-2 (RELAX-AHF-2) - PubMed, accessed September 22, 2025, https://pubmed.ncbi.nlm.nih.gov/39663924/
38. Pharmacokinetics of serelaxin in patients with severe renal impairment or end-stage renal disease requiring hemodialysis: A single-dose, open-label, parallel-group study - ResearchGate, accessed September 22, 2025, https://www.researchgate.net/publication/280693780_Pharmacokinetics_of_serelaxin_in_patients_with_severe_renal_impairment_or_end-stage_renal_disease_requiring_hemodialysis_A_single-dose_open-label_parallel-group_study
39. Population pharmacokinetics of serelaxin in patients with acute or chronic heart failure, hepatic or renal impairment, or portal hypertension and in healthy subjects - PubMed Central, accessed September 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6177704/
40. Population pharmacokinetics of serelaxin in patients with acute or ..., accessed September 22, 2025, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6177704/
41. Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study. - Epistemonikos Database, accessed September 22, 2025, https://www.epistemonikos.org/fr/documents/8b15c83ee0b48156aeb3a15581f1ec853021d0b8?doc_lang=en
42. Abstract 12961: No Effect of Hepatic Impairment on the Pharmacokinetics of Serelaxin, a Recombinant Human Relaxin-2 in Development for the Treatment of Acute Heart Failure | Circulation, accessed September 22, 2025, https://www.ahajournals.org/doi/10.1161/circ.128.suppl_22.A12961?doi=10.1161/circ.128.suppl_22.A12961
43. Study Details | NCT00520806 | Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure | ClinicalTrials.gov, accessed September 22, 2025, https://clinicaltrials.gov/study/NCT00520806
44. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial - UMIC, accessed September 22, 2025, https://www.umic.hc.edu.uy/images/RELAX_HF.pdf
45. Representativeness of RELAX-AHF Clinical Trial Population in Acute Heart Failure | Circulation: Cardiovascular Quality and Outcomes - AHA Journals, accessed September 22, 2025, https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.113.000418
46. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial - PubMed, accessed September 22, 2025, https://pubmed.ncbi.nlm.nih.gov/23141816/
47. Effect of Serelaxin on Mode of Death in Acute Heart Failure: Results From the RELAX-AHF Study - JACC Journals, accessed September 22, 2025, https://www.jacc.org/doi/10.1016/j.jacc.2014.05.071
48. Study Details | NCT01870778 | Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF | ClinicalTrials.gov, accessed September 22, 2025, https://www.clinicaltrials.gov/study/NCT01870778
49. RELAXin in Acute Heart Failure-2 - RELAX-AHF-2 - American College of Cardiology, accessed September 22, 2025, https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2017/05/07/16/09/RELAX-AHF-2
50. Effects of Serelaxin in Patients with Acute Heart Failure - the University of Groningen research portal, accessed September 22, 2025, https://research.rug.nl/files/120354397/Effects_of_Serelaxin_in_Patients_with_Acute_Heart_Failure..pdf
51. RELAX-AHF-2: Lack of Benefit With Serelaxin in Acute HF Still a ..., accessed September 22, 2025, https://www.tctmd.com/news/relax-ahf-2-lack-benefit-serelaxin-acute-hf-still-puzzle-investigators
52. Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2 | JACC, accessed September 22, 2025, https://www.jacc.org/doi/10.1016/j.jchf.2020.09.010
53. RELAX-REPEAT: Multiple Doses of Serelaxin Safe, Tolerable for CHF - Medscape, accessed September 22, 2025, https://www.medscape.com/viewarticle/863962
54. FDA panel rejects serelaxin approval for heart failure, but urges future study - The Hospitalist, accessed September 22, 2025, https://blogs.the-hospitalist.org/content/fda-panel-rejects-serelaxin-approval-heart-failure-urges-future-study
55. FDA Advisory Committee Votes Against Novartis' Serelaxin For Heart Failure, accessed September 22, 2025, https://www.clinicalleader.com/doc/fda-advisory-committee-votes-against-novartis-serelaxin-for-heart-failure-0001
56. FDA grants Breakthrough Therapy status to Novartis' heart failure drug serelaxin, accessed September 22, 2025, https://www.drugdiscoverynews.com/fda-grants-breakthrough-therapy-status-to-novartis-heart-failure-drug-serelaxin-7461
57. FDA staff say Novartis' serelaxin should not be approved for heart ..., accessed September 22, 2025, https://firstwordpharma.com/story/1122745
58. FDA Issues Complete Response Letter for Novartis' RLX030 - PharmTech, accessed September 22, 2025, https://www.pharmtech.com/view/fda-issues-complete-response-letter-novartis-rlx030-0
59. Novartis Receives FDA Complete Response Letter for Serelaxin, accessed September 22, 2025, https://www.dcatvci.org/top-industry-news/novartis-receives-fda-complete-response-letter-for-serelaxin/
60. FDA Issues Complete Response Letter for Novartis' RLX030 - BioPharm International, accessed September 22, 2025, https://www.biopharminternational.com/view/fda-issues-complete-response-letter-novartis-rlx030
61. FDA issues Complete Response Letter for RLX030 for acute heart failure | Fierce Biotech, accessed September 22, 2025, https://www.fiercebiotech.com/biotech/fda-issues-complete-response-letter-for-rlx030-for-acute-heart-failure
62. Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure: A Phase 1a/b, First‐in‐Human, Randomized, Single‐Blind, Placebo‐Controlled Study - AHA Journals, accessed September 22, 2025, https://www.ahajournals.org/doi/10.1161/JAHA.123.034067